Mindray(SZ:300760) Sou Hu Wang·2025-12-13 05:04Core Viewpoint - The continuous share buybacks by the chairman of Mindray Medical reflect confidence in the company's future growth and recovery in performance despite recent challenges [1][2]. Group 1: Share Buyback Activity - On December 9, 2025, the chairman of Mindray Medical, Li Xiting, increased his stake by purchasing 150,600 shares at an average price of 199.12 yuan per share, totaling 29.99 million yuan [1]. - Li Xiting has made four consecutive share purchases since November 27, with cumulative investments exceeding 100 million yuan [1]. - The chairman plans to continue buying shares with a total investment of 200 million yuan over the next six months, without a price range set for the purchases [1]. Group 2: Company Performance and Market Outlook - Despite facing pressure on performance due to high base effects, Mindray Medical reported a year-on-year revenue growth of 1.53% in the third quarter, indicating a potential turning point [1]. - The company anticipates a recovery in domestic business growth next year, with profit growth expected to turn positive by 2026 [1]. - Mindray Medical believes the most challenging period for its domestic business has passed and is focusing on increasing market share, particularly in the IVD sector [2]. Group 3: Strategic Focus and Market Position - The company is leveraging the current market environment to accelerate domestic expansion and enhance industry concentration, with a focus on large-sample clients in the IVD business [2]. - Mindray Medical is investing resources in high-value consumables in minimally invasive surgery, which are expected to grow significantly compared to traditional life support products [2]. - The company aims to rank among the top 20 global medical device manufacturers, maintaining a top-three market share in various product categories such as monitors, anesthesia machines, and ultrasound products [2].